Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315066 · ClinicalTrials.gov registry record · Phase 1
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT02315066 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 174 participants.
The verdict
NCT02315066, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Interventions
- DRUG PF-04518600
- DRUG PF-04518600 plus PF-05082566
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2015-04-23 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02315066
The ClinicalTrials.gov registry entry for NCT02315066 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-04518600 is the first listed.
NCT02315066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02315066 about?
NCT02315066 is a clinical study titled "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566". To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
What is the current status of trial NCT02315066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2015-04-23. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT02315066?
The interventions under investigation include: PF-04518600 (DRUG), PF-04518600 plus PF-05082566 (DRUG).
Who is sponsoring clinical trial NCT02315066?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.